Memory and Mental Health in Aging

NCT ID: NCT02988908

Last Updated: 2017-02-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 198 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2000-04-30
• Study Completion Date: 2007-09-30

Brief Summary

A comparison of memory training with and without donepezil.

Detailed Description

Study 1:

Investigators evaluated the short-term and longer-term efficacy and effectiveness of a pharmacologic augmentation strategy for a nonpharmacologic treatment to improve memory performance in nondemented older adults. Investigators used a randomized controlled trial with parallel groups design that compares two Treatments: DONEPEZIL + COGNITIVE TRAINING versus PLACEBO + COGNITIVE TRAINING.

Study 2:

The second study looked more closely at dosage. Investigators hoped to determine the best dosage of the drug donepezil for enhancing the effects of the memory training program.

Conditions

Memory

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Drug: Donepezil

Participants received Donepezil as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial.

Participants also received 2 weeks of memory training at weeks 13-14

Group Type: EXPERIMENTAL

Donepezil

Intervention Type: DRUG

Participants received donepezil as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial.

Participants also received 2 weeks of memory training at weeks 13-14

Placebo (Control)

Participants received placebo as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial.

Participants also received 2 weeks of memory training at weeks 13-14

Group Type: PLACEBO_COMPARATOR

Placebos

Intervention Type: DRUG

Participants received placebo as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial.

Participants also received 2 weeks of memory training at weeks 13-14

Interventions

Donepezil

Participants received donepezil as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial.

Participants also received 2 weeks of memory training at weeks 13-14

Intervention Type: DRUG

Placebos

Participants received placebo as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial.

Participants also received 2 weeks of memory training at weeks 13-14

Intervention Type: DRUG

Other Intervention Names

Aricept; Control

Eligibility Criteria

Inclusion Criteria

Study 1 only:

1. Global Clinical Dementia Rating (CDR) 0.0 or 0.5, at least 1 Box score = 0.5 and none > 0.5;

2. Laboratory normal B12, RPR, and Thyroid Function Tests or without any clinically significant abnormalities that would be expected to interfere with the study, plus general clinical chemistry and complete blood count.

3. ECG without clinically significant abnormalities that would be expected to interfere with the study

Study 1 and Study 2:

1. Mini-Mental Exam score between 24 and 30 (inclusive);

2. General cognition and functional performance sufficiently preserved such that a diagnosis of Alzheimer's Disease cannot be made by the site physician at the time of the screening visit;

3. Permitted medications stable for at least 1 month prior to screening. In particular: a) Subjects may take stable doses of antidepressants lacking significant anticholinergic side effects (if they are not currently depressed and do not have a history of major depression within the past 2 years). b) Estrogen replacement therapy is permissible. c) Ginkgo biloba is permissible, but discouraged.

4. Hamilton Depression Score less than or equal to 12 on the 17-item scale.

5. Visual and auditory acuity adequate to allow neuropsychological testing.

6. General health good with no additional diseases expected to interfere with the study.

7. Women two years post-menopausal or surgically sterile.

Exclusion Criteria

1. Any significant neurologic disease such as Possible and Probable AD, Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities.

2. Major depression or another major psychiatric disorder as described in DSM IV within the past 2 years. History of schizophrenia (DSM IV criteria). Psychotic features, agitation or behavioral problems within the last 3 months which could lead to difficulty complying with the protocol.

3. History of alcohol or substance abuse or dependence within the past 2 years (DSM IV criteria).

4. Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol including:

1. History of systemic cancer within the last 5 years (non-metastatic skin cancers are acceptable).

2. History of myocardial infarction within the past year or unstable or severe cardiovascular disease including angina or CHF with symptoms at rest.

3. Clinically significant obstructive pulmonary disease or asthma.

4. Clinically significant and unstable gastrointestinal disorder such as ulcer disease or a history of active or occult gastrointestinal bleeding within two years.

5. Insulin-requiring diabetes or uncontrolled diabetes mellitus.

6. Uncontrolled hypertension (systolic BP greater than 170 or diastolic greater than 100).

7. History of clinically significant liver disease, coagulopathy, or vitamin K deficiency within the past 2 years.

5. Use of centrally active beta-blockers, narcotics, methyldopa and clonidine within 4 weeks prior to screening. b) Use of anti-Parkinsonian medications (e.g. Sinemet, amantadine, bromocriptine, pergolide and selegiline) within 2 months prior to screening. c) Use of neuroleptics or narcotic analgesics within 4 weeks prior to screening. d) Use of long-acting benzodiazepines or barbiturates within 4 weeks prior to screening. e) Use of short-acting anxiolytics or sedative hypnotics more frequently than 2 times per week within 4 weeks prior to screening (note: sedative agents should not be used within 72 hours of screening). f) Initiation or change in dose of an antidepressant lacking significant cholinergic side effects within the 4 weeks prior to screening (use of stable doses of antidepressants for at least 4 weeks prior to screening is acceptable). g) Use of systemic corticosteroids within 3 months prior to screening. h) Medications with significant cholinergic or anticholinergic side effects (e.g. pyridostigmine, tricyclic antidepressants, meclizine, and oxybutynin) within 4 weeks prior to screening. i) Use of anti-convulsants (e.g. Phenytoin, Phenobarbital, Carbamazepine) within 2 months prior to screening. j) Use of warfarin (Coumadin) within 4 weeks prior to screening.

6. Any prior use of any FDA approved medications for the treatment of Alzheimer's Disease (e.g. tacrine, donepezil, or other newly approved medications).

7. Use of any investigational drugs within 30 days or 5 half-lives, whichever is longer, prior to screening.

• Minimum Eligible Age: 55 Years
• Maximum Eligible Age: 90 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

National Institute of Mental Health (NIMH)

NIH

Sponsor Role: collaborator

Stanford University

OTHER

Sponsor Role: lead

Responsible Party

Jerome A Yesavage,

Principle Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Jerome A Yesavage

Role: PRINCIPAL_INVESTIGATOR

Stanford University

Locations

VA Palo Alto Health Care System

Palo Alto, California, United States

Countries

United States

Other Identifiers

SU-06302009-2820

Identifier Type: -

Identifier Source: org_study_id

R01MH035182

Identifier Type: NIH

Identifier Source: secondary_id

View Link

eprotocol #7530

Identifier Type: OTHER

Identifier Source: secondary_id